Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.43 |
| ▸ | CEL | P19835 | 2/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 2/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.32 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.32 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4675869 | 0.99 | GPR84 (0.45) | GPR84CELNFE2L2MCL1HPGD | |
| SCHEMBL4670069 | 0.97 | GPR84 (0.41) | GPR84CELNFE2L2MCL1HPGD | |
| SCHEMBL4670034 | 0.96 | GPR84 (0.39) | GPR84CELNFE2L2HPGDDAO | |
| SCHEMBL4670460 | 0.95 | GPR84 (0.41) | GPR84CELNFE2L2HPGDDAO | |
| SCHEMBL4670381 | 0.94 | GPR84 (0.36) | GPR84CELNFE2L2HPGDGRM2 | |
| SCHEMBL4670060 | 0.92 | DAO (0.40) | GPR84CELNFE2L2HPGDDAO | |
| SCHEMBL4675644 | 0.91 | DAO (0.41) | GPR84CELNFE2L2HPGDDAO | |
| SCHEMBL4670123 | 0.90 | DAO (0.37) | GPR84CELNFE2L2HPGDDAO | |
| SCHEMBL4676113 | 0.86 | GPR84 (0.43) | GPR84CELMCL1SPHK1HRH4 | |
| SCHEMBL4675865 | 0.85 | GPR84 (0.45) | GPR84CELMCL1SPHK1HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1054881-B1 | NOVEL SULFONAMIDE SUBSTITUTED CHROMAN DERIVATIVES USEFUL AS BETA-3 ADRENORECEPTOR AGONISTS | BAYER CORP (US) | 2008-07-30 | — | — | EP | disclosed |
| US-6903218-B2 | Sulfonamide substituted chroman derivatives | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-06-07 | — | — | US | disclosed |
| US-20040072843-A1 | Novel sulfonamide substituted chroman derivatives useful as beta 3 adrenoreceptor agonists | LADOUCEUR GAETAN H (US) | 2004-04-15 | — | — | US | disclosed |
| US-20030073839-A1 | Compounds useful for preparation of Beta-3 adrenoreceptor agonist | BAYER PHARMACEUTICALS CORPORATION | 2003-04-17 | — | — | US | disclosed |
| EP-1054881-A1 | NOVEL SULFONAMIDE SUBSTITUTED CHROMAN DERIVATIVES USEFUL AS BETA-3 ADRENORECEPTOR AGONISTS | Bayer Corporation (US) | 2000-11-29 | — | — | EP | disclosed |
| US-6051586-A | HYPOGLYCEMIC AGENTS; ANTIDIABETIC AGENTS | BAYER CORPORATION (US) | 2000-04-18 | — | — | US | disclosed |
| WO-1999032475-A1 | NOVEL SULFONAMIDE SUBSTITUTED CHROMAN DERIVATIVES USEFUL AS BETA-3 ADRENORECEPTOR AGONISTS | BAYER CORPORATION (US) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072843-A1 | Novel sulfonamide substituted chroman derivatives useful as beta 3 adrenoreceptor agonists | ADRB3, ADRB2, ADRB1 | GPR84 50/4885CEL 2437/4885NFE2L2 2675/4885 |
| US-20030073839-A1 | Compounds useful for preparation of Beta-3 adrenoreceptor agonist | ADRB3, ADRB2, ADRB1 | GPR84 129/4885CEL 1874/4885NFE2L2 3069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.